MNG53
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (0 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
8 twins match this tumor's tissue · 2 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR6013594 | — | cohortMD2 | 0.874 |
| 2 | MNG516 | — | — | 0.855 |
| 3 | PL21_HAEMATOPOIETIC_AND_LYMPHOID_TISSUE | AML | — | 0.839 |
| 4 | ERR2208907 | — | — | 0.820 |
| 5 | SRR25617921 | — | C | 0.817 |
| 6 | BV173_HAEMATOPOIETIC_AND_LYMPHOID_TISSUE | CML | — | 0.813 |
| 7 | AUR-AF9A-TTP1-A-1-0-R-A741-41 | — | D | 0.804 |
| 8 | MBCProject_3717_T1_RNA | — | B | 0.803 |
| 9 | MBCProject_1542_T2_RNA | — | D | 0.800 |
| 10 | TCGA-62-A472-01A-11R-A24H-07 | — | cohortA1 | 0.800 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 8 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_GAMMA_RESPONSE | 0.309 | Idelalisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.278 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.243 | Idelalisib | — uncovered |
| E2F_TARGETS | 0.213 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.155 | Idelalisib | — uncovered |
| G2M_CHECKPOINT | 0.081 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.072 | Remibrutinib | — uncovered |
| MYC_TARGETS_V1 | 0.017 | Inavolisib | — uncovered |